To the Editor: The recent introduction of rapid point-of-care testing (PoCT) in Australian pharmacies to screen for coeliac disease has attracted controversy1 and provides an important opportunity to review the current literature.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Jason Tye-Din holds patents pertaining to the use of gluten peptides in therapeutics, diagnostics and non-toxic gluten for coeliac disease. He is a consultant to ImmusanT and a shareholder of Nexpep.